Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histamine SCHEMBL2279 | 1.00 | — | — | |
| Histamine SCHEMBL1668636 | 1.00 | HRH4 (0.42) | HRH4HRH3TSHRCYP2C9CYP2C19 | |
| Histamine SCHEMBL5447892 | 1.00 | — | — | |
| Histamine SCHEMBL27340939 | 1.00 | — | — | |
| Histamine SCHEMBL7444650 | 1.00 | HRH4 (0.42) | HRH4HRH3TSHRCYP2C9CYP2C19 | |
| Histamine SCHEMBL584026 | 0.98 | TDP1 (0.44) | HRH4HRH3TSHRCYP2C9CYP2C19 | |
| Histamine SCHEMBL991718 | 0.98 | — | — | |
| Histamine SCHEMBL931130 | 0.98 | — | — | |
| Histamine SCHEMBL21806473 | 0.98 | — | — | |
| Histamine SCHEMBL6453806 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210505-A2 | FOOD SUPPLEMENT OR MEDICINAL OR PHARMACEUTICAL COMPOSITION INHIBITING VIRUS INFECTION, ADVANTAGEOUSLY INFECTION OF SARS-COV-2 AND IBV CORONAVIRUSES AND FORMULATION THEREOF | Gyulai László (HU) | 2023-07-19 | — | — | EP | claimed |
| WO-2022112806-A2 | FOOD SUPPLEMENT OR MEDICINAL OR PHARMACEUTICAL COMPOSITION INHIBITING VIRUS INFECTION, ADVANTAGEOUSLY INFECTION OF SARS-COV-2 AND IBV CORONAVIRUSES AND FORMULATION THEREOF | GYULAI LASZLO (HU) | 2022-06-02 | — | — | WO | claimed |
| CN-105899074-B | Compounds, compositions and methods for attracting and/or trapping bed bugs | 西蒙弗雷泽大学 | 2019-09-24 | — | — | CN | claimed |
| EP-1226435-A4 | AXOR35, A G-PROTEIN COUPLED RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2004-12-22 | — | — | EP | claimed |
| EP-1226435-A1 | AXOR35, A G-PROTEIN COUPLED RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001033221-A1 | AXOR35, A G-PROTEIN COUPLED RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-10 | — | — | WO | claimed |
| EP-4210505-A2 | FOOD SUPPLEMENT OR MEDICINAL OR PHARMACEUTICAL COMPOSITION INHIBITING VIRUS INFECTION, ADVANTAGEOUSLY INFECTION OF SARS-COV-2 AND IBV CORONAVIRUSES AND FORMULATION THEREOF | Gyulai László (HU) | 2023-07-19 | — | — | EP | disclosed |
| US-20220229077-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | PRECISION MEDICINE HOLDINGS PTY LTD (AU) | 2022-07-21 | — | — | US | disclosed |
| WO-2022112806-A2 | FOOD SUPPLEMENT OR MEDICINAL OR PHARMACEUTICAL COMPOSITION INHIBITING VIRUS INFECTION, ADVANTAGEOUSLY INFECTION OF SARS-COV-2 AND IBV CORONAVIRUSES AND FORMULATION THEREOF | GYULAI LASZLO (HU) | 2022-06-02 | — | — | WO | disclosed |
| WO-2020210642-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | CAMP4 THERAPEUTICS CORPORATION (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3691656-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY | Camp4 Therapeutics Corporation (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3655428-A1 | CHIMERIC RECEPTORS | Oxford University Innovation Limited (GB) | 2020-05-27 | — | — | EP | disclosed |
| EP-3516389-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | Precision Medicine Holdings Pty Ltd (AU) | 2019-07-31 | — | — | EP | disclosed |
| CN-1694691-A | Treatment of metastatic breast cancer with anthracyclines and taxanes | UNIV MANITOBA (CA) | 2005-11-09 | — | — | CN | disclosed |
| EP-1221615-A2 | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy | ORIDIGM CORPORATION (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2000061560-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000056714-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-09-28 | — | — | WO | disclosed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| US-4704273-A | IMMUNOGLOBULIN G PROVOCATIVE OF PHEUMATOID FACTOR FORMATION | MOLECULAR RX, INC. | 1987-11-03 | — | — | US | disclosed |
| US-4277474-A | DERMATITIS, RHINITIS, ASTHMA | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1981-07-07 | — | — | US | disclosed |